Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Novel Diet Approach to Combat Gestational Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03803072
Recruitment Status : Recruiting
First Posted : January 14, 2019
Last Update Posted : March 13, 2019
Sponsor:
Collaborator:
St. Olavs Hospital
Information provided by (Responsible Party):
Norwegian University of Science and Technology

Brief Summary:

There is an urgent need to implement novel diet approaches to combat the increasing rates of gestational diabetes mellitus (GDM). The primary aim of this study is to establish the feasibility of time-restricted eating in pregnancy, to prepare for future larger controlled trials in this research project to determine the efficacy of time-restricted eating in women at risk of GDM. Expectations:

  1. Women who have an increased risk of GDM will be able to adhere to time reduced eating during pregnancy.
  2. Time reduced eating will improve short-term glycemic control in pregnancy.

Condition or disease Intervention/treatment Phase
Diabetes, Gestational Behavioral: time restricted eating (TRE) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Novel Diet Approach to Combat Gestational Diabetes
Actual Study Start Date : January 18, 2019
Estimated Primary Completion Date : October 31, 2019
Estimated Study Completion Date : October 31, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Time restricted eating (TRE)
prolonging the duration of fasting between the last evening meal and the first meal of the next day
Behavioral: time restricted eating (TRE)
Participants will attend a face-to-face meeting with the researchers at the last day of the first week of data collection (habitual diet and physical activity period) where they will be counselled to consume all food and fluid within a 8-10 h time window of their choice starting no later than 09.00 h for five weeks. During the intervention period, they will be counselled by weekly phone calls to provide encouragement, support and monitoring to improve adherence to the TRE window.

No Intervention: control
Standard care. Will receive a booklet about physical activity recommendations and healthy eating in pregnancy



Primary Outcome Measures :
  1. Change in average time-window for energy intake [ Time Frame: Change between baseline (pre-intervention) time-window for energy intake to average time-window for energy intake during the 5-week intervention period ]
    Average daily time-window for energy intake will be registered through log books.

  2. Weekly adherence rates for time restricted eating (TRE) [ Time Frame: Weekly measures throughout the 5 week period of TRE intervention ]
    The number of days per week that the participants are able to adhere to TRE, as calculated as weekly average of days with a time-window ≤ 10 hours


Secondary Outcome Measures :
  1. Perceived barriers to the protocol assessed with an unstructured interview [ Time Frame: Weekly phone calls to participants in TRE group during the 5-week intervention period and after 6 weeks ]
    Participants will be asked about which barriers they perceived as challenging regarding keeping to a TRE schedule and if they have strategies to overcome these barriers.

  2. Subjective appetite sensations assessed by Visual Analogue Scales [ Time Frame: Once weekly throughout 6 weeks, on a weekday. ]
    Paper line scales 100 mm on scales for Hunger ("How hungry are you": From "Not at all" = 0 on the scale to "Extremely. As hungry as I have ever felt" =100 on the scale, Fullness (From "Not at all" = 0 on the scale to "Extremely. As full as I have ever felt" = 100 on the scale, Satiety ("How satiated are you" From "Not at all" =0 on the scale to "Extremely" =100 on the scale, Desire to eat ("How strong is your desire to eat" From "Very weak. Extremely low" = 0 on the scale to "Very strong. Extremely high" = 100 on the scale and Prospective consumption (quantity) ("How much do you think you could (or would want to) eat right now?" From "Nothing at all" = 0 on the scale to "A very large amount" = 100 on the scale. Scales will be filled in in the morning, before dinner and at bedtime.

  3. Change between baseline and post-intervention in fasting glucose [ Time Frame: 6 weeks ]
    Post-intervention fasting glucose minus pre-intervention fasting glucose

  4. Change between baseline and post-intervention in postprandial glucose [ Time Frame: 6 weeks ]
    Blood glucose levels 120 minutes after ingestion of 75 g glucose (oral glucose tolerance test)

  5. Change between baseline and post-intervention in fasting insulin [ Time Frame: 6 weeks ]
    Circulating insulin levels

  6. Change between baseline and post-intervention in postprandial insulin [ Time Frame: 6 weeks ]
    Circulating insulin levels 120 minutes after ingestion of 75 g glucose.

  7. Change between baseline and post-intervention blood pressure [ Time Frame: 6 weeks ]
    Diastolic and systolic blood pressure

  8. Change between baseline and post-intervention body mass [ Time Frame: 6 weeks ]
    Body mass in kg.

  9. Change in total cholesterol [ Time Frame: 6 weeks ]
    Total cholesterol measured in blood

  10. Change in triglycerides [ Time Frame: 6 weeks ]
    Triglycerides measured in blood

  11. Change in HDL cholesterol [ Time Frame: 6 weeks ]
    HDL cholesterol measured in blood

  12. Change in LDL cholesterol [ Time Frame: 6 weeks ]
    LDL cholesterol measured in blood

  13. Change in HbA1c [ Time Frame: 6 weeks ]
    HbA1c measured in blood

  14. Continuous glucose monitoring [ Time Frame: 6 weeks ]
    Interstitial glucose measurements

  15. Change between baseline and post-intervention fat mass [ Time Frame: 6 weeks ]
    Fat mass in kg and percent of body mass

  16. Change between baseline and post-intervention muscle mass [ Time Frame: 6 weeks ]
    Muscle mass in kg

  17. Change between baseline and post-intervention visceral fat area [ Time Frame: 6 weeks ]
    Visceral fat area in squared cm.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • carrying one singleton live foetus
  • in pregnancy week 12-30
  • having at least one risk factor for gestational diabetes mellitus (GDM) according to Norwegian guidelines for GDM screening: pre-pregnancy BMI > 25 kg/m2, GDM in previous pregnancy, primiparae aged > 25 years, first degree relative with diabetes mellitus, Asian or African ethnicity, previous delivery of new-born > 4.5 kg
  • understand written and spoken Norwegian language

Exclusion Criteria:

  • habitual eating window < 12 hours

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03803072


Contacts
Layout table for location contacts
Contact: Trine Moholdt, phd 0047 97098594 trine.moholdt@ntnu.no
Contact: Kirsti Garnæs, phd

Locations
Layout table for location information
Norway
St Olavs Hospital Recruiting
Trondheim, Norway
Contact: Ola Berger, phd         
Sponsors and Collaborators
Norwegian University of Science and Technology
St. Olavs Hospital
Investigators
Layout table for investigator information
Study Director: Øystein Risa, phd Department of circulation and medical imaging, NTNU

Layout table for additonal information
Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT03803072     History of Changes
Other Study ID Numbers: 2018/2271
First Posted: January 14, 2019    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Norwegian University of Science and Technology:
Exercise therapy
Diet
Prevention and control

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes, Gestational
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pregnancy Complications